Regeneron (REGN) Tops Q2 EPS by 75c

August 2, 2018 6:38 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Regeneron (NASDAQ: REGN) reported Q2 EPS of $5.45, $0.75 better than the analyst estimate of $4.70. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.56 billion.

  • Second quarter 2018 GAAP net income per diluted share increased by 44% to $4.82 versus second quarter 2017 and second quarter 2018 non-GAAP net income per diluted share increased 31% to $5.45 versus second quarter 2017
  • Second quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 8% to $992 million versus second quarter 2017 and second quarter 2018 EYLEA global net sales(1) increased 13% to $1.66 billion versus second quarter 2017
  • Positive results reported from Phase 3 trial of Dupixent® (dupilumab) in adolescents with inadequately controlled moderate-to-severe atopic dermatitis


The Company's updated full year 2018 financial guidance consists of the following components:

Sanofi collaboration revenue: Sanofi reimbursement of Regeneron commercialization-related expenses

$455 million–$485 million

(previously $450 million–$485 million)

Non-GAAP unreimbursed R&D(2)(4)

$1.210 billion$1.260 billion

(previously $1.230 billion–$1.310 billion)

Non-GAAP SG&A(2)(4)

$1.340 billion–$1.390 billion

(previously $1.325 billion–$1.395 billion)

Effective tax rate


(previously 15%–18%)

Capital expenditures

$410 million$450 million

(previously $420 million–$480 million)

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Hot Earnings